OmniAb (OABI) Total Non-Current Liabilities (2021 - 2026)
OmniAb (OABI) posted quarterly Total Non-Current Liabilities of $30.9 million for Q1 2026, down 5.06% year-over-year from $32.6 million in Q1 2025, and down 8.52% quarter-over-quarter from $33.8 million in Q4 2025.
OmniAb (OABI) Total Non-Current Liabilities (2021 - 2026) Analysis & Trends
OmniAb (OABI) has reported Total Non-Current Liabilities for 6 consecutive years, with $30.9 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Total Non-Current Liabilities fell 5.06% year-over-year to $30.9 million; the TTM figure through Mar 2026 stood at $30.9 million (down 5.06% YoY), while the FY2025 annual figure was $33.8 million, down 10.69% from the prior year.
- Total Non-Current Liabilities eased to $30.9 million in Q1 2026 per OABI's latest filing, from $33.8 million in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $79.8 million in Q4 2022 and bottomed at $30.9 million in Q1 2026.
- Historically, Total Non-Current Liabilities has averaged $48.3 million across 5 years, with a median of $41.4 million in 2024.
- Annual changes were most pronounced in 2022 — Total Non-Current Liabilities climbed 22.13% — and 2024, when it slumped 37.5%.
- OmniAb's Total Non-Current Liabilities stood at $79.8 million in 2022, then fell by 28.02% to $57.4 million in 2023, then slumped by 34.09% to $37.9 million in 2024, then declined by 10.69% to $33.8 million in 2025, then decreased by 8.52% to $30.9 million in 2026.
- Business Quant data shows OABI's Total Non-Current Liabilities at $30.9 million in Q1 2026, $33.8 million in Q4 2025, and $32.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 40.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 1.53 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.88 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.32 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.20 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.17 Bn |
| 10 | OmniAb | 491.42 Mn | 439.42 Mn | 12.81 Mn | 29.02 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 29.02 Mn |
| Mar 31, 2026 | 30.93 Mn |
| Dec 31, 2025 | 33.81 Mn |
| Sep 30, 2025 | 32.17 Mn |
| Jun 30, 2025 | 33.53 Mn |
| Mar 31, 2025 | 32.58 Mn |
| Dec 31, 2024 | 37.85 Mn |
| Sep 30, 2024 | 39.77 Mn |
| Jun 30, 2024 | 43.03 Mn |
| Mar 31, 2024 | 51.13 Mn |
| Dec 31, 2023 | 57.44 Mn |
| Sep 30, 2023 | 63.64 Mn |
| Jun 30, 2023 | 68.05 Mn |
| Mar 31, 2023 | 72.20 Mn |
| Dec 31, 2022 | 79.79 Mn |
| Dec 31, 2021 | 65.33 Mn |